Jerrold B. Grossman

This profile gathers the share dealings of Jerrold B. Grossman in Adma Biologics, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 25 October 2021 to 27 May 2026, the count stands at 13 filings.

The open-market side counts 5 purchases for €741k alongside 1 sale for €186k. Taken together, the purchases exceed the sales by €554k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 5 share grants and 2 option exercises. In 2026 alone, the filings show 3 purchases and no sales.

In size, the median ticket on the buying side is €85k. Measured against the company's value, the median purchase equals 0.0044% of market capitalisation, across 3 purchases where it is known. Of 5 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 28 May 2026 with an open-market purchase (€44k) in Adma Biologics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.